CA-ODASEVA
12.9.2019 14:02:14 CEST | Business Wire | Press release
Odaseva , the unified cloud data protection, compliance and operations platform for enterprises running Salesforce as a business-critical application, today announced that it has seen triple year over year growth, and after only seven years of operation, supports a staggering one trillion Salesforce records, with over 10 million enterprise-level internal Salesforce customers.
Odaseva’s explosive growth is in part due to the influx of new data privacy and governance laws such as GDPR or CCPA , demanding that businesses put in place specific regulations such as Data Subject Rights (which stipulates that consumers have the right to access their own private information) and leverage more robust data governance solutions to shield and manage private customer information. Odaseva, which began in 2012 with one client, Schneider Electric, has rapidly increased its enterprise customer base including Toyota France, Robert Half International and GE, offering organizations the ability to augment their existing cloud data protection solutions.
“Comprehensive compliance automation and data protection are essential for organizations coping with increasingly complex and costly privacy regulations as varied as HIPAA, GDPR, CCPA and PIPEDA,” says Sovan Bin, founder and CEO of Odaseva. “As confidential personal data is often distributed across multiple clouds, as well as on-premises data centers, our goal at Odaseva has been to introduce consistency in how audit information is gathered and presented as well as preserved, in order to provide a measure of relief for businesses striving to comply with multiple regulations.
“No other technology vendor today can offer such a unified cloud data governance suite for Salesforce as Odaseva,” Sovan Bin continued.
Recent Investments and Increased Headcount
In 2019, Odaseva raised $11.7m in Series A funding round, which brought the total funding for Odaseva to $14 million. The round was led by Partech with participation from new investor Salesforce Ventures and existing investor Serena. These new investments have allowed Odaseva to direct a portion of the new funding to build on existing sales and technology partnerships with Accenture, Capgemini, CGI, and Deloitte.
In addition, Odaseva has doubled their headcount in the past six months with new hires including a new chief legal officer and a vice president of customer and partner success.
Located in San Francisco and Paris, Odaseva continues to actively recruit in both locations and is looking to expand its operations globally.
Added New Products to Portfolio Line-up:
The hallmark of Odaseva’s solution lies in its compliance automation tools such as GDPR for Salesforce which allows the enterprise to automate a broad range of data procedures from backup to archival, audit, and more in order to comply with industry regulations.
However in 2019 alone, Odaseva announced several new tools to complete their portfolio that have included the following:
- Cockpit AI: With advanced machine learning capabilities, Cockpit AI offers the first predictive capacity management system to help enterprise Salesforce users maximize the value of the platform by automating the process of monitoring and forecasting the use of platform allocations – such as file storage, data storage and API calls on Salesforce
- Vault: Works with the Odaseva platform to help users automatically archive sensitive data that organizations are required to keep for long periods of time in regulated industries such as financial services, healthcare and insurance. Not only will the information be kept safe from any unauthorized users, but Odaseva ensures a data durability level of 99.999999999% over a given year.
- Full Sandbox Anonymization application (FSA) for Salesforce customers . The application works with the Odaseva platform to anonymize all personal information that an organization may put in a Salesforce Full Sandbox – which is an isolated copy of an organization’s Salesforce environment that can be used for training, development and testing.
About Odaseva
For enterprises that leverage Salesforce as a mission-critical application, Odaseva delivers enterprise-class data governance, providing data protection (backup and recovery, archiving, governor limits monitoring), data compliance for regulation requirements such as GDPR and data operations (Salesforce DX data extensions). Odaseva was engineered for Salesforce by Salesforce experts and is endorsed by Salesforce Ventures. Over 10+Million Salesforce Enterprise users from industry-leading companies such as Schneider Electric, Heineken and Robert Half trust Odaseva’s data governance platform.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005206/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom